Personalized Therapy Shows Promise in Metastatic Breast Cancer

Share this content:
Researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer.
Researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer.

(HealthDay News) -- A highly personalized therapy targeting multiple tumor antigens shows promise for metastatic breast cancer, according to a research letter published online June 4 in Nature Medicine.

Nikolaos Zacharakis, Ph.D., from the National Institutes of Health in Bethesda, Md., and colleagues present the case of a 49-year-old woman with chemorefractory hormone receptor-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes that were reactive against mutation versions of four proteins (SLC3A2, KIAA0368, CADPS2, and CTSB).

The researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer, with the target tumor burden reduced by 51 percent at the first evaluable time points six weeks after cell transfer. At 22 months after cell transfer, all target and nontarget lesions had resolved radiologically.

"Metastatic breast cancer can be a heterogeneous disease, and this patient demonstrated that a personalized therapy tailored to target the unique somatic mutations presented by the autologous tumor of the affected individual can mediate complete durable cancer regression," the authors write.

Abstract/Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs